For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Participants are included in Cohort 1 - Augment if they meet the following criteria:
- Adults18 years or older
- Diagnosis of histologically confirmed R/M SCCHN, from any of the following primary sites only: oral cavity, oropharynx, hypopharynx, and larynx between 01-Jun-2017 and 31-June-2018.
- Prescribed 1L treatment for R/M SCCHN
- Treatment history and response available for medical chart abstraction from date of diagnosis until death or the end of the study in living participants
- Have available for review one month of follow-up data available post initiation of 1L R/M SCCHN therapy
- Informed consent form (ICF) signature/collection of living participants, as required by country regulation and local ethics committees
Participants are included in Cohort 1 if they meet the following criteria:
- Adults 18 years or older
- Diagnosis of histologically confirmed R/M SCCHN, from any of the following primary sites only: oral cavity, oropharynx, hypopharynx and larynx between 01-Jan-2014 and 31-Dec-2016.
- Prescribed 1L treatment for R/M SCCHN
- Treatment history and response available for medical chart abstraction from the date of diagnosis until death or the end of the study in living participants
- Have available for review one month of follow-up data post initiation of 1L R/M SCCHN therapy
- Informed consent form (ICF) signature/collection of living participants, as required by country regulation and local ethics committees
Exclusion Criteria:
Participants were excluded from either cohort if they meet the following criteria:
- Were enrolled in a cancer treatment-related clinical trial since the diagnosis of R/M SCCHN
- Recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary site, squamous cell carcinoma that originated from the skin and salivary gland or non-squamous histologies (e.g., mucosal melanoma).